作者: Daniel H Palmer , Syed A Hussain , Philip J Johnson
DOI: 10.1517/13543784.13.12.1555
关键词:
摘要: For the minority of patients with hepatocellular carcinoma (HCC), surgical or locally ablative therapies may offer prospect cure. However, majority present advanced disease such that treatment curative intent is no longer possible. some these patients, good hepatic reserve and a patent portal venous system, chemoembolisation afford modest survival benefit. The remainder are frequently treated systemic palliative intent. This review aims to summarise current approaches for HCC in adjuvant setting before reviewing evidence novel emerging this field. At there number interesting therapeutic agents potential activity HCC. challenge now design clinical trials optimally evaluate agents.